Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, specifically chronic hepatitis B (cHBV). It develops imdusiran (AB-729), a GalNAc-conjugated subcutaneous RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor, both targeting cHBV functional cure. The company also owns patented lipid nanoparticle (LNP) technology licensed via Genevant Sciences, and is pursuing patent infringement litigation against Pfizer/BioNTech and has settled with Moderna for $950 million noncontingent payment.
Q2 FY2026 — expected 2026-09-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001447028-26-000017 | EDGAR | 66K words |
| 2025-03-27 | 2024-12-31 | 0001447028-25-000083 | EDGAR | 66K words |
| 2024-03-05 | 2023-12-31 | 0001447028-24-000035 | EDGAR | 64K words |
| 2023-03-02 | 2022-12-31 | 0001447028-23-000018 | EDGAR | 66K words |
| 2022-03-03 | 2021-12-31 | 0001447028-22-000019 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001447028-21-000021 | EDGAR | — |
| 2020-03-05 | 2019-12-31 | 0001447028-20-000038 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001447028-19-000006 | EDGAR | — |
| 2018-03-16 | 2017-12-31 | 0001628280-18-003276 | EDGAR | — |
| 2017-03-22 | 2016-12-31 | 0001628280-17-002760 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001447028-26-000045 | EDGAR | 24K words |
| 2025-11-13 | 2025-09-30 | 0001447028-25-000126 | EDGAR | 24K words |
| 2025-08-06 | 2025-06-30 | 0001447028-25-000115 | EDGAR | 23K words |
| 2025-05-14 | 2025-03-31 | 0001447028-25-000099 | EDGAR | 22K words |
| 2024-11-06 | 2024-09-30 | 0001447028-24-000087 | EDGAR | 24K words |
| 2024-08-08 | 2024-06-30 | 0001447028-24-000072 | EDGAR | 24K words |
| 2024-05-02 | 2024-03-31 | 0001447028-24-000038 | EDGAR | 23K words |
| 2023-11-07 | 2023-09-30 | 0001447028-23-000090 | EDGAR | 26K words |
| 2023-08-03 | 2023-06-30 | 0001447028-23-000082 | EDGAR | 26K words |
| 2023-05-04 | 2023-03-31 | 0001447028-23-000025 | EDGAR | 25K words |
| 2022-11-09 | 2022-09-30 | 0001447028-22-000055 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001447028-22-000047 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-21 | 0001104659-26-099390 | EDGAR | 1K words |
| 2026-08-12 | 0001171843-26-005442 | EDGAR | 3K words |
| 2026-07-16 | 0001171843-26-004708 | EDGAR | 2K words |
| 2026-03-23 | 0001171843-26-001838 | EDGAR | 3K words |
| 2026-03-03 | 0001171843-26-001299 | EDGAR | 1K words |
| 2026-02-20 | 0001171843-26-000979 | EDGAR | 6K words |
| 2026-02-06 | 0001171843-26-000676 | EDGAR | 11K words |
| 2026-01-16 | 0001171843-26-000303 | EDGAR | 1K words |
| 2025-12-11 | 0001171843-25-007879 | EDGAR | 2K words |
| 2025-11-13 | 0001171843-25-007256 | EDGAR | 3K words |
527 total filings indexed. 495 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001447028 |
| Ticker | ABUS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | A1 |
| Headquarters | Warminster, Pennsylvania |
| Website | http://www.arbutusbio.com |
| Listed | 2007-07-26 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ABUS (~200 tokens, structured JSON with cryptographic provenance)